Skip to main content
    P

    Palvella Therapeutics, Inc (PVLA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $144.60
    -7.88 (-5.17%)

    Market Cap: $2.23B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Palvella Therapeutics, Inc (PVLA) Financials: Revenue, Profit and Cash Flow

    Updated Nov 5, 2026. Financial statements from company filings, amounts in US dollars.

    Palvella Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$41.72M, operating cash flow was -$25.01M and free cash flow was -$25.01M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$24.64M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $38.60M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0-100.0%N/AN/AN/A
    Dec 2022$25.90M-17.6%89.3%-167.8%-128.5%
    Dec 2021$31.42M+7.1%92.5%-165.0%-145.6%
    Dec 2020$29.32M-36.6%100.0%-115.7%-127.0%
    Dec 2019$46.28M+59.0%N/A-58.7%-55.0%
    Dec 2018$29.10M+15.1%N/A-105.9%-91.9%
    Dec 2017$25.27M+333.5%N/A-57.7%-69.8%
    Dec 2016$5.83MN/AN/A-390.3%-391.0%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$0$0$0$25.90M$31.42M$29.32M$46.28M$29.10M$25.27M$5.83M
    Cost of revenueN/AN/AN/A$2.78M$2.37MN/AN/AN/AN/AN/A
    Gross profitN/AN/AN/A$23.12M$29.05M$29.32MN/AN/AN/AN/A
    Research and development$22.84M$8.15M$8.79M$50.21M$64.20M$44.22M$54.36M$40.92M$21.92M$19.70M
    Operating income-$38.60M-$14.10M-$11.87M-$43.47M-$51.83M-$33.92M-$27.16M-$30.83M-$14.59M-$22.76M
    Net income-$41.72M-$17.43M$18.69M-$33.28M-$45.74M-$37.23M-$25.47M-$26.75M-$17.65M-$22.80M
    EBITDA-$35.90M-$13.12M$18.69M-$30.50M-$43.37MN/A-$24.43M-$26.50MN/A-$22.28M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0$0$0$0$0$0$0$0$53.00K$1.30M
    Gross profitN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A$1.30M
    Operating income-$22.73M-$21.41M-$14.86M-$11.30M-$10.18M-$9.25M-$7.87M-$4.37M-$5.06M-$2.91M-$1.76M-$5.48M
    Net income-$24.64M-$21.87M-$15.77M-$12.71M-$11.35M-$9.47M-$8.19M-$3.95M-$6.78M-$4.17M-$2.54M-$4.58M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $202.00K by $57.78M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$59.56M$88.23M$7.55M$16.52M$153.56M$105.01MN/AN/AN/AN/A
    Current assets$58.99M$88.23M$7.55M$16.52M$127.63M$75.72MN/AN/AN/AN/A
    Cash and equivalents$57.98M$83.60M$7.35M$16.05M$117.76M$70.44MN/AN/AN/AN/A
    Total liabilities$31.58M$25.63M$11.43M$39.70M$102.81M$73.98MN/AN/AN/AN/A
    Short-term debt$202.00KN/AN/A$859.00K$1.05M$1.03MN/AN/AN/AN/A
    Shareholder equity$27.98M$62.61M-$3.88M-$23.17M$50.76M$31.03MN/AN/AN/AN/A
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$239.40M$253.51M$263.76M$59.56M$66.94M$73.75M$79.44M$88.23M$20.52M$25.05M$6.39M$38.68M
    Total liabilities$41.48M$36.58M$31.45M$31.58M$28.25M$25.97M$23.86M$25.63M$4.25M$6.35M$12.66M$11.92M
    Cash and equivalents$193.30M$187.80M$206.39M$57.98M$63.57M$70.43M$75.63M$83.60M$19.36M$19.73M$6.25M$17.40M
    Shareholder equity$197.92M$216.87M$232.31M$27.98M$38.68M$47.78M$55.58M$62.61M$16.27M$18.70M-$6.27M$26.76M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
    Operating cash flow-$25.01M-$10.84M-$13.70M-$14.84M-$7.66M-$45.90M
    Capital expenditures$0$0$0$1.04M$949.00K$2.73M
    Free cash flow-$25.01M-$10.84M-$13.70M-$15.88M-$8.61M-$48.62M
    Investing cash flowN/AN/AN/A-$21.24M-$949.00K$39.21M
    Financing cash flow-$660.00K$87.09M$5.00M$9.57M$59.13M$10.12M
    Fiscal years ended Dec 2020 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$14.43M-$12.85M-$10.86M-$4.93M-$7.88M-$5.43M-$6.77M-$5.39M-$2.74M-$1.60M-$1.10M-$19.67M
    Capital expenditures$0$0$0$0$0$0$0$13.00K$0$0$0$13.00K
    Free cash flow-$14.43M-$12.85M-$10.86M-$4.93M-$7.88M-$5.43M-$6.77M-$5.41M-$2.74M-$1.60M-$1.10M-$19.68M
    Last 12 quarters

    Frequently Asked Questions About PVLA

    What is Palvella Therapeutics' annual revenue?

    Palvella Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Palvella Therapeutics profitable?

    No. Palvella Therapeutics reported net income of -$41.72M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does PVLA generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$25.01M minus capital expenditures of $0 produced free cash flow of -$25.01M.

    How much debt does Palvella Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $202.00K and cash and equivalents of $57.98M.